A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features

N. Ruperto; P. Quartier; N.M. Wulffraat; P. Woo; A. Ravelli; R. Mouy; B. Bader-Meunier; S.J. Vastert; E. Noseda; D. D'Ambrosio; J. Lecot; A.B. Chakraborty; A. Martini; A. Chioato

doi:10.1002/art.33342

A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features

N. Ruperto, P. Quartier, N.M. Wulffraat, P. Woo, A. Ravelli, R. Mouy, B. Bader-Meunier, S.J. Vastert, E. Noseda, D. D'Ambrosio, J. Lecot, A.B. Chakraborty, A. Martini, A. Chioato

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	557-67
Number of pages	11
Journal	Arthritis and Rheumatism
Volume	64
Issue number	2
DOIs	https://doi.org/10.1002/art.33342
Publication status	Published - 2012

Access to Document

10.1002/art.33342

http://onlinelibrary.wiley.com/doi/10.1002/art.33342/pdf

Cite this

Ruperto, N., Quartier, P., Wulffraat, N. M., Woo, P., Ravelli, A., Mouy, R., Bader-Meunier, B., Vastert, S. J., Noseda, E., D'Ambrosio, D., Lecot, J., Chakraborty, A. B., Martini, A., & Chioato, A. (2012). A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis and Rheumatism, 64(2), 557-67. https://doi.org/10.1002/art.33342

@article{99603da87de34f9da9a2728302ceb44c,

title = "A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features",

author = "N. Ruperto and P. Quartier and N.M. Wulffraat and P. Woo and A. Ravelli and R. Mouy and B. Bader-Meunier and S.J. Vastert and E. Noseda and D. D'Ambrosio and J. Lecot and A.B. Chakraborty and A. Martini and A. Chioato",

year = "2012",

doi = "10.1002/art.33342",

language = "English",

volume = "64",

pages = "557--67",

journal = "Arthritis and Rheumatism",

issn = "0004-3591",

publisher = "John Wiley & Sons Inc.",

number = "2",

}

Ruperto, N, Quartier, P, Wulffraat, NM, Woo, P, Ravelli, A, Mouy, R, Bader-Meunier, B, Vastert, SJ, Noseda, E, D'Ambrosio, D, Lecot, J, Chakraborty, AB, Martini, A & Chioato, A 2012, 'A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features', Arthritis and Rheumatism, vol. 64, no. 2, pp. 557-67. https://doi.org/10.1002/art.33342

A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. / Ruperto, N.; Quartier, P.; Wulffraat, N.M. et al.
In: Arthritis and Rheumatism, Vol. 64, No. 2, 2012, p. 557-67.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features

AU - Ruperto, N.

AU - Quartier, P.

AU - Wulffraat, N.M.

AU - Woo, P.

AU - Ravelli, A.

AU - Mouy, R.

AU - Bader-Meunier, B.

AU - Vastert, S.J.

AU - Noseda, E.

AU - D'Ambrosio, D.

AU - Lecot, J.

AU - Chakraborty, A.B.

AU - Martini, A.

AU - Chioato, A.

PY - 2012

Y1 - 2012

U2 - 10.1002/art.33342

DO - 10.1002/art.33342

M3 - Article

C2 - 21953497

SN - 0004-3591

VL - 64

SP - 557

EP - 567

JO - Arthritis and Rheumatism

JF - Arthritis and Rheumatism

IS - 2

ER -